FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2985679614> ?p ?o ?g. }

• W2985679614 endingPage "1668" @default.
• W2985679614 startingPage "1668" @default.
• W2985679614 abstract "Background. MPN are clonal disorders of hematopoietic stem cell (HSC) that include polycythemia vera (PV), essential thrombocytemia (ET) and myelofibrosis (MF), either secondary to ET-PV, or primary (PMF), including pre-fibrotic (pre-PMF) and overt. In MF, multi-lineage dysplasia (MLD) of varying degree can be detected by morphologic analysis of bone marrow (BM), but appraisal of MLD is intrinsically operator-dependent and lacks quantitative information. Multi-parameter flow cytometry (MFC) is used to study dysplasia by investigating aberrant antigen expression profiles during hematopoietic cells' differentiation and maturation, allowing: i) analysis of a much greater cell number; ii) standardization of data by referring to controls; iii) definition of scores to estimate MLD extent. Aim. The aim of the study was to assess MLD in MPN by MFC and correlate with disease' variant, clinical and biological features. Methods. Patients: pts were diagnosed according to 2016 WHO criteria. Driver and high molecular risk mutations (HMR) were determined. MFC: Different BM cell compartments were analyzed with a panel of 28 monoclonal antibodies (MoAb) by 2 acquisition steps: Step 1) HSC and progenitor (GMP and MEP) cells up to >5 x 106 cells/sample were studied by Lin/CD34/CD38/CD90/CD45/CD49f/CD45RA/CD135 MoAb. Step 2) Precursor and mature compartments (B-, neutrophilic, monocytic, erythroid, plasmacytoid dendritic cells, basophils) were identified within CD34+ and/or CD117+ subset. Uncommitted CD38+ precursors were obtained by subtraction. CD117-neg, maturing cells were identified by specific features, ie CD34, CD45 and scatter. MLD was assessed by 2 phenotypic scores: i) one validated by ELN in MDS (Ogata score) includes 4 parameters; ii) the second one, adapted from Matarraz et al (2010; Salamanca score), 63 parameters. Normal phenotypic profile was defined as the interval between mean value (M) ± 2SD per parameter in healthy donors' BM samples. Each parameter scored 0.5, 1 or 2 for values between M ± 2 SD and M ± 3 SD, M ± 3 SD and M ± 4 SD, and over M ± 4 SD of the normal profile, respectively. Results. 51 consecutive MPN pts at diagnosis were enrolled, including 30 MF (7 pre-PMF, 14 overt PMF, 9 post-PV/ET MF); 13 ET, 5 PV, 1 MPN-unclassifiable and 2 MDS/MPN. Median age was 59y (range 24-83). 19 (63.3%) MF patients had JAK2V617F, 9 (30.0%) CALR, 2 (6.7%) MPLW515L mutation. 11 pts (36.7%) harbored at least 1 HMR mutation. According to MIPSS, 6 (20.0%), 11 (36.7%) and 10 (33.3%) were low, intermediate and high risk. By comparing MF pts to controls and ET-PV, altered proportion of immature cell subsets was observed. Specifically, HSC and uncommitted progenitors in MF were increased of 3.8 and 1.5-fold, respectively whereas GMP and downstream precursors were significantly reduced 2 to >6-fold. No significant differences emerged comparing mature compartments, except for an increase of basophils and a decrease of pDC in MF subset (Table 1). When considering MLD, MF patients ranked higher scores for both the Ogata and Salamanca score. Furthermore, Salamanca score values had a trend to correlate with MIPSS risk categories, with median value of 7.75, 13.25 and 15.5 in low, intermediate and high category (KW test P=0.06). MF cases were separated according to Salamanca score ≥ or < to the median value of 13.5: pts with higher score were featured by significant differences in hemoglobin (11.9 vs 13.7 g/dL; P=.015), platelet count (330 vs 558 x109/L; P=.004), LDH (380 vs 275 U/L; P=.034), circulating CD34+ cells (60.4 vs 5.3/mL; P=.007). We also compared prePMF and ET pts, two categories with challenging differential diagnosis: prePMF displayed expansion of HSC (0.015) compared to ET (0.0056; P=0.028) and reduced proportions of downstream precursors, similar to what observed in MF vs non-MF comparison. Conversely, MLD scores were similar: Ogata 1.0 vs 1.0, Salamanca 9.0 vs 7.5 for ET and prePMF, respectively. Conclusions. The assessment of MLD by MFC correlated with MPN variants according to WHO; MF was associated with higher deviation from normal phenotypic profile. MLD scores delineated clinical phenotype and were consistent with MIPSS risk stratification. With the limits of number of pts analyzed, these preliminary data also support a biologic continuum of pre-PMF and MF, the first being characterized by abnormal expansion of immature cell compartments compared to ET but minimal signs of dysplastic maturation unlike overt MF. Disclosures Vannucchi: Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Italfarmaco: Membership on an entity's Board of Directors or advisory committees; CTI BioPharma: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau." @default.
• W2985679614 created "2019-11-22" @default.
• W2985679614 creator A5011711495 @default.
• W2985679614 creator A5013539196 @default.
• W2985679614 creator A5018165235 @default.
• W2985679614 creator A5031007022 @default.
• W2985679614 creator A5032323700 @default.
• W2985679614 creator A5035375378 @default.
• W2985679614 creator A5036108661 @default.
• W2985679614 creator A5046292780 @default.
• W2985679614 creator A5046772202 @default.
• W2985679614 creator A5064238460 @default.
• W2985679614 creator A5065223581 @default.
• W2985679614 creator A5065805805 @default.
• W2985679614 date "2019-11-13" @default.
• W2985679614 modified "2023-10-16" @default.
• W2985679614 title "Multi-Lineage Dysplasia Assessment By Immunophenotype in Myeloproliferative Neoplasms (MPN): Correlation with Disease' Variant, Clinical Features and Molecular Genetics" @default.
• W2985679614 doi "https://doi.org/10.1182/blood-2019-125843" @default.
• W2985679614 hasPublicationYear "2019" @default.
• W2985679614 type Work @default.
• W2985679614 sameAs 2985679614 @default.
• W2985679614 citedByCount "1" @default.
• W2985679614 countsByYear W29856796142021 @default.
• W2985679614 crossrefType "journal-article" @default.
• W2985679614 hasAuthorship W2985679614A5011711495 @default.
• W2985679614 hasAuthorship W2985679614A5013539196 @default.
• W2985679614 hasAuthorship W2985679614A5018165235 @default.
• W2985679614 hasAuthorship W2985679614A5031007022 @default.
• W2985679614 hasAuthorship W2985679614A5032323700 @default.
• W2985679614 hasAuthorship W2985679614A5035375378 @default.
• W2985679614 hasAuthorship W2985679614A5036108661 @default.
• W2985679614 hasAuthorship W2985679614A5046292780 @default.
• W2985679614 hasAuthorship W2985679614A5046772202 @default.
• W2985679614 hasAuthorship W2985679614A5064238460 @default.
• W2985679614 hasAuthorship W2985679614A5065223581 @default.
• W2985679614 hasAuthorship W2985679614A5065805805 @default.
• W2985679614 hasBestOaLocation W29856796141 @default.
• W2985679614 hasConcept C10205521 @default.
• W2985679614 hasConcept C109159458 @default.
• W2985679614 hasConcept C142724271 @default.
• W2985679614 hasConcept C159912055 @default.
• W2985679614 hasConcept C196166836 @default.
• W2985679614 hasConcept C201750760 @default.
• W2985679614 hasConcept C203014093 @default.
• W2985679614 hasConcept C2775894508 @default.
• W2985679614 hasConcept C2776839831 @default.
• W2985679614 hasConcept C2779282312 @default.
• W2985679614 hasConcept C2780007613 @default.
• W2985679614 hasConcept C2780076729 @default.
• W2985679614 hasConcept C2780817109 @default.
• W2985679614 hasConcept C28328180 @default.
• W2985679614 hasConcept C54355233 @default.
• W2985679614 hasConcept C553184892 @default.
• W2985679614 hasConcept C71924100 @default.
• W2985679614 hasConcept C86803240 @default.
• W2985679614 hasConceptScore W2985679614C10205521 @default.
• W2985679614 hasConceptScore W2985679614C109159458 @default.
• W2985679614 hasConceptScore W2985679614C142724271 @default.
• W2985679614 hasConceptScore W2985679614C159912055 @default.
• W2985679614 hasConceptScore W2985679614C196166836 @default.
• W2985679614 hasConceptScore W2985679614C201750760 @default.
• W2985679614 hasConceptScore W2985679614C203014093 @default.
• W2985679614 hasConceptScore W2985679614C2775894508 @default.
• W2985679614 hasConceptScore W2985679614C2776839831 @default.
• W2985679614 hasConceptScore W2985679614C2779282312 @default.
• W2985679614 hasConceptScore W2985679614C2780007613 @default.
• W2985679614 hasConceptScore W2985679614C2780076729 @default.
• W2985679614 hasConceptScore W2985679614C2780817109 @default.
• W2985679614 hasConceptScore W2985679614C28328180 @default.
• W2985679614 hasConceptScore W2985679614C54355233 @default.
• W2985679614 hasConceptScore W2985679614C553184892 @default.
• W2985679614 hasConceptScore W2985679614C71924100 @default.
• W2985679614 hasConceptScore W2985679614C86803240 @default.
• W2985679614 hasIssue "Supplement_1" @default.
• W2985679614 hasLocation W29856796141 @default.
• W2985679614 hasOpenAccess W2985679614 @default.
• W2985679614 hasPrimaryLocation W29856796141 @default.
• W2985679614 hasRelatedWork W1493158144 @default.
• W2985679614 hasRelatedWork W150914752 @default.
• W2985679614 hasRelatedWork W1988241631 @default.
• W2985679614 hasRelatedWork W2353996467 @default.
• W2985679614 hasRelatedWork W2410107327 @default.
• W2985679614 hasRelatedWork W2531136773 @default.
• W2985679614 hasRelatedWork W2531493050 @default.
• W2985679614 hasRelatedWork W2551029969 @default.
• W2985679614 hasRelatedWork W2952050877 @default.
• W2985679614 hasRelatedWork W3167248648 @default.
• W2985679614 hasVolume "134" @default.
• W2985679614 isParatext "false" @default.
• W2985679614 isRetracted "false" @default.
• W2985679614 magId "2985679614" @default.
• W2985679614 workType "article" @default.